HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

Pre-IPO Edding Group - CSO Model Is Hard to Sustain, but Business Transformation Faces Challenges

Interpretation of China’s Politburo – The A-Share Bull Market Is Coming?

China Healthcare Weekly (Jul.28) - Starting Point of New Prosperity, MNCs Change Strategy, Genscript

BeiGene (6160.HK/​BGNE.US) - AbbVie‘s Patent Infringement Allegations Are Not as Simple as Imagined

The Cyclicality of China Healthcare - Policy Environment, the Industry, and Investment Opportunities

The Truth of China Medical Insurance Fund - Time to Clarify Misunderstandings with Investors

China Traditional Chinese Medicine (570.HK) - The Privatization Rumor and the Outlook

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>In the absence of significant decline in total pharmaceutical expenditure,the most simple logic tells us if some companies/varieties suffer loss in VBP, it inevitably means other companies benefit from it. </li>
<li>For innovative drugs, imported drugs have clear advantage over domestic drugs in both absolute and relative increments. But leading MNCs have been more impacted by VBP in recent years.</li>
<li>In this hundreds-of-billion-level payment transfer process, companies are actually competing to provide real clinical value, which is the key to fill the gap caused by VBP and restore companies’ growth.</li>
</ul>


In the absence of significant decline in total pharmaceutical expenditure,the most simple logic tells us if some companies/varieties suffer loss in VBP, it inevitably means other companies benefit from it. 
For innovative drugs, imported drugs have clear advantage over domestic drugs in both absolute and relative increments. But leading MNCs have been more impacted by VBP in recent years.
In this hundreds-of-billion-level payment transfer process, companies are actually competing to provide real clinical value, which is the key to fill the gap caused by VBP and restore companies’ growth.


China's VBP Policy for Pharmaceuticals – Misunderstandings, Real Impacts, and Outlook